zentalis.comCrawled Nov 6, 2026
Zentalis evaluates azenosertib, an oral WEE1 inhibitor, in clinical trials for ovarian cancer and other tumors.
Discover Zentalis' science: advancing azenosertib, a potential first-in-class, highly selective WEE1 inhibitor to transform treatment for ovarian cancer and beyond.
Zentalis is developing an oral, non-chemotherapy treatment for Cyclin E1-positive platinum-resistant ovarian cancer.
Zentalis Pharmaceuticals’ pipeline includes azenosertib, a late-stage WEE1 inhibitor for ovarian cancer.
Access peer-reviewed publications from Zentalis Pharmaceuticals on azenosertib, WEE1 inhibition, and biomarker-driven oncology research strategies.
Zentalis offers careers in oncology research and development for a distributed team creating cancer treatments.
Meet Zentalis Pharmaceuticals' leadership team of seasoned oncology executives advancing novel cancer therapies from discovery through commercialization.
Zentalis partners with organizations to expand access to azenosertib and its oncology pipeline through global collaborations.
Zentalis Pharmaceuticals provides information about its oncology programs for patients, healthcare providers, and media.
Zentalis Pharmaceuticals is a clinical-stage company advancing azenosertib, a first-in-class WEE1 inhibitor, for ovarian cancer and other tumor types.
The page explains how Zentalis Pharmaceuticals handles personal data collected from website visitors and service users.
Zentalis Pharmaceuticals announces its management team will attend Guggenheim's 3rd Annual Healthcare Innovation Conference in Boston on November 10. The company focuses on late-stage development of **azenosertib**, a WEE1 inhibitor for biomarker-driven ovarian cancer treatment. This event includes a fireside discussion with investors.
Nov 2026ir.zentalis.comNews article
Zentalis Pharmaceuticals reports a **15.9-month median overall survival** in patients with **Cyclin E1-positive platinum-resistant ovarian cancer (PROC)** treated with **azenosertib** in the **DENALI Part 1b trial**. The study included patients with **1–5 prior lines of therapy**, and the drug’s safety profile remained consistent with earlier findings. The **84.6% median relative dose intensity** confirms high exposure to the treatment. These interim results further support **Cyclin E1 protein expression** as a predictive biomarker for azenosertib’s efficacy in this cancer subtype.
Oct 2026ir.zentalis.comNews article
Zentalis Pharmaceuticals reports **15.8-month median overall survival** in patients with **Cyclin E1-positive platinum-resistant ovarian cancer** treated with **azenosertib monotherapy**. The data, derived from the **DENALI Part 1b trial**, will be presented as a rapid oral session at the **ESMO Congress 2026** on October 23, 2026. The findings highlight progress in biomarker-driven oncology therapies for aggressive cancer subtypes.
Oct 2026ir.zentalis.comNews article
Zentalis Pharmaceuticals closes a public offering of **26.45 million shares** of common stock, including **3.45 million additional shares** purchased by underwriters. The company, focused on oncology, develops **azenosertib**, a WEE1 inhibitor for biomarker-driven ovarian cancer treatment. The funding supports late-stage clinical trials of its investigational therapy.
Aug 2026ir.zentalis.comNews article
